The amendment came in as a two-page addendum to an existing contract. One partner reviewed it, saw a per-member-per-month payment that looked like an increase, and signed. Eighteen months later, the practice is carrying downside risk on a quality measure computed from claims nobody in the building can reproduce, on a panel attributed by a formula nobody read, with a reconciliation arriving in a quarter and no rule anywhere about which partner absorbs the penalty. Nothing about the signature was fraudulent. The problem is that a single physician was contractually able to reprice the practice’s revenue for years, and the agreement never said otherwise.
Payer contracts are among the most consequential documents a practice signs. They set the price of nearly every service the practice delivers, they carry timely-filing and recoupment clocks that decide what those prices are actually worth, and they run for years with automatic renewal. A partnership agreement that carefully governs a $50,000 equipment purchase and says nothing about a contract governing 30 percent of collections has its thresholds pointed at the wrong risk.
Start by separating two things that get conflated: the authority to negotiate and the authority to execute. Someone has to carry the conversation with the payer—a managing partner, an administrator, or a retained consultant—and that mandate should be explicit, bounded, and renewable. Execution is a different act. Routine fee-for-service participation agreements and their amendments belong at the significant tier, decided by partner vote at simple majority on a noticed agenda, with the rate schedule and the material terms circulated in advance. The negotiator brings back a recommendation. The partners sign the practice’s name.
Risk-bearing arrangements move up a tier, and the agreement should say so in those words. Any contract that puts practice revenue at risk on performance—capitation, shared savings with a downside component, withholds, quality penalties, or any arrangement in which missing a target costs the practice money—requires a full partner vote, and a supermajority where the group can carry it. The reason is reversibility again. A fee schedule that disappoints can be renegotiated at the next cycle. A risk contract that goes wrong can consume a year of margin before the reconciliation even lands.
Before any such contract is signed, five questions need answers in writing. Which metrics, defined how, and measured by whom—with the payer’s exact specification, its exclusions and data sources, and the underlying member-level data rather than a scorecard, because a measure the practice cannot independently recompute is a measure it can neither manage nor dispute. How attribution works: which children count as the practice’s, assigned by claims history, member selection, or geography, and how newborns, plan-switchers, and patients who never come in despite outreach enter the denominator. What the realistic dollar range is, modeled at the practice’s actual panel and historical measure rates rather than at the headline. Where the downside sits and who bears it. And, where the terms are vague, what the reconciliation timeline, the appeal process, and the mid-measurement-year termination rule actually are—the answers exist in the payer’s model contract, and their absence from this one is not an accident.
Downside risk deserves a specific caution in pediatrics. Pediatric spending is dominated by a small number of catastrophic cases—a neonatal intensive care unit graduate, an oncology diagnosis—that no primary care behavior controls, and a risk pool small enough to be swung by two patients is a lottery ticket rather than a contract. That does not make every value-based arrangement a bad deal; care-coordination payments and achievable process measures are frequently the most winnable part of a Medicaid negotiation. It makes the downside page the one that gets read twice and voted on once.
Then decide the internal allocation before it matters. If the practice accepts quality bonuses, shared savings, penalties, or withholds, the agreement states how those dollars distribute among the partners: by attributed panel, by individual measure performance, or shared practice-wide as a cost of doing business. Each is defensible; each produces a different number; and the one that produces a fight is the one chosen after the first reconciliation arrives. Note the structural fact that makes individual attribution harder than it looks—these formulas are computed from claims rather than charts, which means each physician’s coding is her quality score, and a screening performed but never billed is invisible to the payer’s arithmetic.
Scale the governance to the portfolio. A practice with six contracts needs a named negotiator and a vote. A practice with 20, spread across commercial plans, Medicaid managed care organizations, and a clinically integrated network, needs a standing managed care committee with a charter: who sits on it, what it may decide, what it must bring to the partners, and how it reports. And every practice needs the calendar. Maintain a contract register with effective dates, rate schedules, termination windows, and renegotiation dates, and put a full payer review on the annual partnership meeting agenda. Automatic renewal is a decision the practice makes by failing to make it, and a group that learns its termination window has closed has already chosen next year’s rates.
One legal note belongs on the record without being turned into advice. Joint negotiation with other independent practices raises federal antitrust questions, and the answer depends on the structure—messenger models, clinically integrated networks, and independent practice associations are treated differently, and the analysis is fact-specific. That is a conversation to have with counsel before any conversation with another practice, not after.
The pediatric stakes are concentrated, which is what makes the drafting urgent. A four-physician practice collecting roughly $2.6 million with a panel 44 percent Medicaid does not have a diversified payer portfolio. It has two or three relationships that decide whether the year works, and an amendment to any one of them is a partnership-level event whatever the envelope calls it.
Red flags. A managing partner who signs payer contracts alone. A capitation or risk arrangement accepted without any partner understanding where the downside sits. No governance distinction between a fee-for-service participation agreement and a risk-bearing one. Quality penalty and bonus allocation left undefined. And partners who cannot name their own contracts’ renewal dates or renegotiation windows.
A contract nobody voted for can still bind everybody. Define the authority now, while the only thing at stake is a paragraph.
Not under a well-drafted agreement. The mandate to negotiate can sit with a managing partner, an administrator, or a retained consultant, and it should be explicit, bounded, and renewable. Execution is a different act: routine participation agreements and their amendments are decided by partner vote at simple majority, with the rate schedule and material terms circulated in advance.
Five questions need answers in writing: which metrics, defined how and measured by whom; how attribution assigns patients to the practice; the realistic dollar range modeled at the practice's actual panel and historical measure rates; where the downside sits and who bears it; and the reconciliation timeline, appeal process, and mid-measurement-year termination rule.
The agreement states the allocation before it matters: by attributed panel, by individual measure performance, or shared practice-wide as a cost of doing business. Each is defensible, and each produces a different number. The allocation that produces a fight is the one chosen after the first reconciliation arrives.